Fredun Pharmaceuticals Limited (BOM:539730)
India · Delayed Price · Currency is INR 1,278.70
-46.60 (-3.52%)
At close: Sep 9, 2025
Fredun Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 4,936 | 4,517 | 3,466 | 2,743 | 2,217 | 1,316 | Upgrade |
Other Revenue | 37.39 | 45.62 | 15.79 | 3.34 | 27.23 | 22.64 | Upgrade |
| 4,973 | 4,563 | 3,482 | 2,747 | 2,245 | 1,338 | Upgrade | |
Revenue Growth (YoY) | 36.28% | 31.05% | 26.75% | 22.37% | 67.74% | 18.74% | Upgrade |
Cost of Revenue | 3,748 | 3,476 | 2,757 | 2,191 | 1,843 | 1,070 | Upgrade |
Gross Profit | 1,225 | 1,087 | 724.71 | 555.79 | 401.99 | 268 | Upgrade |
Selling, General & Admin | 583.06 | 537.71 | 344.89 | 278.02 | 252.54 | 177.37 | Upgrade |
Other Operating Expenses | 27.72 | - | -1.12 | -1.97 | 7.33 | -1.54 | Upgrade |
Operating Expenses | 664.89 | 588.11 | 381.73 | 304.14 | 284.58 | 195.88 | Upgrade |
Operating Income | 560.11 | 498.7 | 342.99 | 251.65 | 117.41 | 72.12 | Upgrade |
Interest Expense | -249.96 | -223.77 | -125.18 | -75.62 | -43.91 | -38.4 | Upgrade |
Interest & Investment Income | - | - | 0.14 | 0.23 | 0.06 | 0.25 | Upgrade |
Currency Exchange Gain (Loss) | - | - | 7.19 | 13.85 | 11.81 | 0.55 | Upgrade |
Other Non Operating Income (Expenses) | - | - | -10.62 | -15.94 | 0.64 | -2.46 | Upgrade |
EBT Excluding Unusual Items | 310.15 | 274.94 | 214.52 | 174.18 | 86 | 32.07 | Upgrade |
Other Unusual Items | - | - | - | - | - | -11.64 | Upgrade |
Pretax Income | 310.15 | 274.94 | 214.52 | 175.09 | 86 | 32.07 | Upgrade |
Income Tax Expense | 86.4 | 77.54 | 58.29 | 67.02 | 22.65 | 11.92 | Upgrade |
Net Income | 223.75 | 197.39 | 156.23 | 108.07 | 63.35 | 20.15 | Upgrade |
Net Income to Common | 223.75 | 197.39 | 156.23 | 108.07 | 63.35 | 20.15 | Upgrade |
Net Income Growth | 28.95% | 26.34% | 44.57% | 70.58% | 214.45% | 5.93% | Upgrade |
Shares Outstanding (Basic) | 4 | 4 | 5 | 4 | 4 | 4 | Upgrade |
Shares Outstanding (Diluted) | 4 | 4 | 5 | 4 | 4 | 4 | Upgrade |
Shares Change (YoY) | -5.61% | -5.15% | 3.66% | 7.85% | 4.06% | 0.01% | Upgrade |
EPS (Basic) | 50.75 | 44.83 | 33.66 | 24.13 | 15.26 | 5.05 | Upgrade |
EPS (Diluted) | 50.75 | 44.83 | 33.66 | 24.13 | 15.26 | 5.05 | Upgrade |
EPS Growth | 36.61% | 33.20% | 39.48% | 58.14% | 202.19% | 5.92% | Upgrade |
Free Cash Flow | - | -351.69 | -80.78 | -239.03 | -66.66 | -12.18 | Upgrade |
Free Cash Flow Per Share | - | -79.87 | -17.40 | -53.38 | -16.05 | -3.05 | Upgrade |
Dividend Per Share | 0.700 | 0.700 | 0.700 | 0.700 | 0.700 | 0.700 | Upgrade |
Dividend Growth | - | - | - | - | - | 6.06% | Upgrade |
Gross Margin | 24.63% | 23.82% | 20.82% | 20.23% | 17.91% | 20.03% | Upgrade |
Operating Margin | 11.26% | 10.93% | 9.85% | 9.16% | 5.23% | 5.39% | Upgrade |
Profit Margin | 4.50% | 4.33% | 4.49% | 3.93% | 2.82% | 1.51% | Upgrade |
Free Cash Flow Margin | - | -7.71% | -2.32% | -8.70% | -2.97% | -0.91% | Upgrade |
EBITDA | 613.75 | 549.1 | 380.41 | 279.3 | 138.74 | 91.94 | Upgrade |
EBITDA Margin | 12.34% | 12.03% | 10.93% | 10.17% | 6.18% | 6.87% | Upgrade |
D&A For EBITDA | 53.64 | 50.39 | 37.42 | 27.65 | 21.33 | 19.82 | Upgrade |
EBIT | 560.11 | 498.7 | 342.99 | 251.65 | 117.41 | 72.12 | Upgrade |
EBIT Margin | 11.26% | 10.93% | 9.85% | 9.16% | 5.23% | 5.39% | Upgrade |
Effective Tax Rate | 27.86% | 28.20% | 27.17% | 38.28% | 26.33% | 37.17% | Upgrade |
Revenue as Reported | 4,973 | 4,563 | 3,491 | 2,765 | 2,261 | 1,353 | Upgrade |
Advertising Expenses | - | - | 11 | 0.99 | 4.58 | 1.57 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.